IN BRIEF: Syncona investee Spur reports "encouraging" drug trial data
Syncona Ltd - London-based investor in healthcare companies - Portfolio company Spur Therapeutics Ltd announces new data from its gene therapy programmes in Gaucher disease, adrenomyeloneuropathy (AMN) and GBA1 Parkinson's disease, presented at the annual meeting of the American Society of Gene & Cell Therapy. Read More